Pharmaceutical Composition of Siponimod Patent Published

The European Patent Office (EPO) published patent application EP4633611A1 concerning a pharmaceutical composition of Siponimod on March 18, 2026. The patent application was filed by Synthon B.V. and lists NOGUEIRAS NIETO, Luis, ALVAREZ FERNANDEZ, Lisardo, and KUMAR, Rohit as inventors. This publication pertains to the designated states within the European Union.

Plectranthus Amboinicus Extract for Radiation Skin Disorders

The European Patent Office has published patent application EP4543425A1 concerning a Plectranthus Amboinicus extract for alleviating radiation-induced skin disorders. The patent is assigned to Oneness Biotech Co., Ltd. and lists LU, Kung-Ming, CHEN, Shyi-Gen, and CHEN, Jui-Ching as inventors.

HER2 Nanobody Preparation Method Patent

The European Patent Office has published patent application EP2024001510A1 concerning a preparation method for a HER2 nanobody and conjugate, filed by Fudan University. The patent application details specific IPC classifications related to antibodies, conjugates, and their therapeutic uses, particularly in treating cancer.

EPO Patent Bulletin: Solid State Forms of Zipalertinib

The European Patent Office published patent application EP4630120A1 concerning solid state forms of Zipalertinib and a process for its preparation. The application was filed by Assia Chemical Industries Ltd. and lists Pavel Kolesa, Jana Romanová, and Alexandr Jegorov as inventors.

Lipid Nanoparticles Lyophilization Methods and Compositions Patent

The European Patent Office has published patent application EP4633609A1 concerning methods and compositions for lyophilizing lipid nanoparticles. The patent was published on March 18, 2026, with Global Life Sciences Solutions Canada ULC listed as the applicant.

EPO Patent Publication: Anti-GDF 15 Antibody for Cancer Neoadjuvant Therapy

The European Patent Office has published patent application EP4634222A1 concerning an anti-GDF 15 antibody for the neoadjuvant therapy of cancer, filed by CatalYm GmbH. This publication details the invention and designated states for patent protection.

EPO Patent Publication EP4629997A1: ASBT Inhibitors for Renal Disease Treatment

The European Patent Office has published patent application EP4629997A1 concerning ASBT inhibitors for the treatment of renal diseases, filed by Albireo AB. The publication date is March 18, 2026.

EPO Patent Application: Antibodies Targeting Itga2 and Antibody-Drug Conjugates

The European Patent Office published patent application EP4545563A1 concerning antibodies targeting Itga2 and antibody-drug conjugates. The application lists Foreseen Technology (Beijing) Co., Ltd. and Foreseen Biotechnology (Shanghai) Co., Ltd. as applicants.

EPO Patent Bulletin: Method for Determining Anticancer Treatment Efficacy

The European Patent Office has published patent application EP4634406A1 detailing a method for determining and improving the potential efficacy of anticancer treatments. The patent application lists ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS and other research institutions as applicants.

EPO Patent Publication: Novel Human Antiviral Genes

The European Patent Office published patent application EP4630033A1 on March 18, 2026, detailing novel human antiviral genes related to prokaryotic systems. The application was filed by Institut National de la Santé et de la Recherche Médicale, Université Paris Cité, and Institut Curie.